Search
EHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement
On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.
Read moreShining a Light on Blood Cancer
EHA Launches Digital Campaign
In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.
Publications
The EBMT/EHA CAR-T Cell Handbook
Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele. 2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).
First CMML guidelines produced by EHA, now available
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.
Read moreEHA-ISHBT Hematology Tutorial
Date: March 1-3, 2024
Format: In-Person
Location: Hyderabad, India
Chairs: P. K.
May 8 - International Thalassaemia Day
Every year on the 8th May, Thalassaemia International Federation commemorates the International Thalassaemia Day and organises activities for raising awareness about the genetic blood disorder of thalassaemia, on general topics regarding its prevention, management and cure.
Read moreAddressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA
In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.
Read moreEHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion
In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.
Read moreRelease of the First Handbook on CAR-T Cells in Europe
Barcelona, 9, February, 2022 – The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA 4th European CAR-T Cell Meeting (Feb 10-12, 2022, Virtual).
Read more